脉血康胶囊联合桂哌齐特治疗急性脑梗死的临床研究

目的研究脉血康胶囊联合马来酸桂哌齐特注射液治疗急性脑梗死的临床疗效。方法选取2016年8月—2018年8月北京市房山区良乡医院收治的134例急性脑梗死患者作为研究对象,采用照抽签方式将所有患者分为对照组和治疗组,每组各67例。对照组静脉滴注马来酸桂哌齐特注射液,4支/次,溶于10%的葡萄糖注射液500 mL中,100 mL/h,1次/d;治疗组在对照组治疗的基础上口服脉血康胶囊,3粒/次,3次/d。两组均持续治疗2周。观察两组患者的临床疗效,同时比较两组治疗前后的美国国立卫生研究院卒中量表(NIHSS)评分、改良的Rankin残障量表(MRS)评分、Barthel指数(BI)和血液流变学指标。结果治疗后,对照组和治疗组患者的总有效率分别为85.07%、95.52%,两组比较差异具有统计学意义(P0.05)。治疗后,两组患者NIHSS评分、MRS评分显著降低,BI指数显著升高,同组治疗前后比较差异具有统计学意义(P0.05);治疗后,治疗组NIHSS评分、MRS评分均显著低于对照组,治疗组BI指数显著高于对照组,两组比较差异具有统计学意义(P0.05)。治疗后,两组红细胞压积(HCT)、全血黏度(WBV)和纤维蛋白原(FIB)水平显著降低,同组治疗前后比较差异具有统计学意义(P0.05);治疗后,治疗组血液流变学指标显著低于对照组,两组比较差异具有统计学意义(P0.05)。结论脉血康胶囊联合马来酸桂哌齐特注射液治疗急性脑梗死具有较好的临床疗效,能够降低血液黏度,改善日常活动能力,促进神经功能恢复,具有一定的临床推广应用价值。

Clinical study on Maixuekang Capsules combined with cinepazide in treatment of acute cerebral infarction

Objective To study the clinical efficacy of Maixuekang Capsules combined with Cinepazide Maleate Injection in treatment of acute cerebral infarction. Methods Patients (134 cases) with acute cerebral infarction in Liangxiang Hospital of Fangshan District in Beijing from August 2016 to August 2018 were divided into control and treatment groups by lottery, and each group had 67 cases. Patients in the control group were iv administered with Cinepazide Maleate Injection, 4 tubes/times, added into 10% Glucose Injection 500 mL, 100 mL/h, once daily. Patients in the treatment group were po administered with Maixuekang Capsules on the basis of control gruop, 3 grains/time, three times daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacy was evaluated, and the NIHSS scores, MRS scores, BI, and hemorheology indexes in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups was 85.07% and 95.52%, respectively, and there were differences between two groups (P < 0.05). After treatment, the NIHSS scores and MRS scores in two groups were significantly decreased, but BI in two groups were significantly increased, and the difference was statistically significant in the same group (P< 0.05). After treatment, the NIHSS scores and MRS scores in the treatment group were significantly lower than those in the control group, but BI in the treatment group was significantly higher than those in the control group, with significant difference between two groups (P< 0.05). After treatment, the levels of HCT, WBV, and FIB in two groups were significantly decreased, and the difference was statistically significant in the same group (P< 0.05). After treatment, the hemorheology indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P< 0.05). Conclusion Maixuekang Capsules combined with Cinepazide Maleate Injection has a good clinical effect in treatment of acute cerebral infarction, can reduce blood viscosity, improve the ability of daily activities, and promote the recovery of nerve function, which has a certain clinical application value.